Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lifelong effect of therapy in young patients with the <i>COL4A5</i> Alport missense variant p.(Gly624Asp): a prospective cohort study

10 Jan 2022

Abstract excerpt

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEis) have evolved as a first-line therapy for delaying end-stage renal failure (ESRF) in Alport syndrome (AS). The present study tested the hypothesis of a superior nephroprotective potential of an early ACEi intervention, examining a cohort with the COL4A5 missense variant p.(Gly624Asp). METHODS: In this observational cohort study (NCT02378805), 114...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Connective tissue disorders research
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35022790
DOI: 10.1093/ndt/gfac006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lifelong effect of therapy in young patients with the <i>COL4A5</i> Alport missense variant p.(Gly624Asp): a prospective cohort studyPMID 35022790Read ↗

Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.Semantic proximity Read ↗

COL4A5-p.Gly624Asp is the Predominant Variant in Europe Associated With a Mild Alport Syndrome PhenotypeSemantic proximity Read ↗

Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children.Semantic proximity Read ↗

An update on the pathomechanisms and future therapies of Alport syndrome.Semantic proximity Read ↗

Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.Semantic proximity Read ↗

Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.Semantic proximity Read ↗

Quantifying associations of genotype, proteinuria and eGFR with long-term kidney outcomes in Alport Syndrome using data from the UK National Registry of Rare Kidney Diseases (RaDaR)Semantic proximity Read ↗

Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport syndromeSemantic proximity Read ↗

A review of clinical characteristics and genetic backgrounds in Alport syndrome.Semantic proximity Read ↗

Current and Future Therapeutical Options in Alport Syndrome.Semantic proximity Read ↗

Early Clinical Manifestations and Long-term Renal Outcomes by Genotype in Children with X-Linked Alport SyndromeSemantic proximity Read ↗

Genotype-Phenotype Correlations in Alport Syndrome-A Single-Center Experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.